[5] Marks, L.B.; Yorke, E.D.; Jackson, A.; Ten Haken, R.K.; Constine, L.S.; Eisbruch, A.; Bentzen, S.M.; Nam, J.; Deasy, J.O.
Use of Normal Tissue Complication Probability Models in the Clinic.
Int. J. Radiat. Oncol. Biol. Phys. 2010, 76, S10–S19.

[6] Diez, P.; Hanna, G.G.; Aitken, K.L.; van As, N.; Carver, A.; Colaco, R.J.; Conibear, J.; Dunne, E.M.; Eaton, D.J.; Franks, K.N.; et al.
UK 2022 Consensus on Normal Tissue Dose–Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy.
Clin. Oncol. 2022, 34, 288–300.

[7] Hanna, G.G.; Murray, L.; Patel, R.; Jain, S.; Aitken, K.L.; Franks, K.N.; van As, N.; Tree, A.; Hatfield, P.; Harrow, S.; et al.
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.
Clin. Oncol. 2018, 30, 5–14.

[10] Grimm, J.; LaCouture, T.; Croce, R.; Yeo, I.; Zhu, Y.; Xue, J.
Dose Tolerance Limits and Dose–Volume Histogram Evaluation for Stereotactic Body Radiotherapy.
J. Appl. Clin. Med. Phys. 2011, 12, 267–292.

[25] NCCN Clinical Practice Guidelines in Oncology—Non‑Small Cell Lung Cancer, v5.2022.
Available online: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 (accessed 31 July 2022).

[26] NCCN Clinical Practice Guidelines in Oncology—Esophageal and Esophagogastric Junction Cancers, v4.2022.
Available online: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1433 (accessed 7 September 2022).

[28] NCCN Clinical Practice Guidelines in Oncology—Anal Cancer, v2.2022.
Available online: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1414 (accessed 2 September 2022).

[30] Dapper, H.; Rodríguez, I.; Münch, S.; Peeken, J.C.; Borm, K.; Combs, S.E.; Habermehl, D.
Impact of VMAT‑IMRT Compared to 3D Conformal Radiotherapy on Anal Sphincter Dose Distribution in Neoadjuvant Chemoradiation of Rectal Cancer.
Radiat. Oncol. 2018, 13, 237.

[31] Jadon, R.; Higgins, E.; Hanna, L.; Evans, M.; Coles, B.; Staffurth, J.
A Systematic Review of Dose–Volume Predictors and Constraints for Late Bowel Toxicity Following Pelvic Radiotherapy.
Radiat. Oncol. 2019, 14, 1–14.

[32] Peng, X.; Zhou, S.; Liu, S.; Li, J.; Huang, S.; Jiang, X.; Lin, M.; Huang, S.; Lin, C.; Qian, C.; et al.
Dose–Volume Analysis of Predictors for Acute Anal Toxicity after Radiotherapy in Prostate Cancer Patients.
Radiat. Oncol. 2019, 14, 1–9.

[33] Atkins, K.M.; Chaunzwa, T.L.; Lamba, N.; Bitterman, D.S.; Rawal, B.; Bredfeldt, J.; Williams, C.L.; Kozono, D.E.; Baldini, E.H.; Nohria, A.; et al.
Association of Left Anterior Descending Coronary Artery Radiation Dose with Major Adverse Cardiac Events and Mortality in Patients with Non‑Small Cell Lung Cancer.
JAMA Oncol. 2021, 7, 206–219.

[34] Brodin, N.P.; Tomé, W.A.
Revisiting the Dose Constraints for Head and Neck OARs in the Current Era of IMRT.
Oral Oncol. 2018, 86, 8–18.

[35] Merlotti, A.; Alterio, D.; Vigna‑Taglianti, R.; Muraglia, A.; Lastrucci, L.; Manzo, R.; Gambaro, G.; Caspiani, O.; Miccichè, F.; Deodato, F.; et al.
Technical Guidelines for Head and Neck Cancer IMRT on Behalf of the Italian Association of Radiation Oncology—Head and Neck Working Group.
Radiat. Oncol. 2014, 9, 264.

[36] Brunner, T.B.; Haustermans, K.; Huguet, F.; Morganti, A.G.; Mukherjee, S.; Belka, C.; Krempien, R.; Hawkins, M.A.; Valentini, V.; Roeder, F.
ESTRO ACROP Guidelines for Target Volume Definition in Pancreatic Cancer.
Radiother. Oncol. 2021, 154, 60–69.

[37] Eekers, D.B.P.; In ’t Ven, L.; Roelofs, E.; Postma, A.; Alapetite, C.; Burnet, N.G.; Calugaru, V.; Coremans, I.E.M.; Høyer, M.; et al.
The EPTN Consensus‑Based Atlas for CT‑ and MR‑Based Contouring in Neuro‑Oncology.
Radiother. Oncol. 2018, 128, 37–42.

[38] Inoue, H.K.; Seto, K.I.; Nozaki, A.; Torikai, K.; Suzuki, Y.; Saitoh, J.I.; Noda, S.E.; Nakano, T.
Three‑Fraction CyberKnife Radiotherapy for Brain Metastases in Critical Areas: Referring to the Risk Evaluating Radiation Necrosis and the Surrounding Brain Volumes Circumscribed with a Single‑Dose Equivalence of 14 Gy (V14).
J. Radiat. Res. 2013, 54, 727–735.

[39] Niyazi, M.; Brada, M.; Chalmers, A.J.; Combs, S.E.; Erridge, S.C.; Fiorentino, A.; Grosu, A.L.; Lagerwaard, F.J.; Minniti, G.; Mirimanoff, R.O.; et al.
ESTRO‑ACROP Guideline “Target Delineation of Glioblastomas.”
Radiother. Oncol. 2016, 118, 35–42.

[40] Scoccianti, S.; Detti, B.; Gadda, D.; Greto, D.; Furfaro, I.; Meacci, F.; Simontacchi, G.; Di Brina, L.; Bonomo, P.; Giacomelli, I.; et al.
Organs at Risk in the Brain and Their Dose‑Constraints in Adults and Children: A Radiation Oncologist’s Guide for Delineation in Everyday Practice.
Radiother. Oncol. 2015, 114, 230–238.

[41] Li, B.; Li, D.; Lau, D.H.; Farwell, D.G.; Clark, C.H.; Clementel, E.; Corning, C.; Ebert, M.; Hoskin, P.; Hurkmans, C.W.; et al.
Clinical‑Dosimetric Analysis of Measures of Dysphagia Including Gastrostomy‑Tube Dependence among Head and Neck Cancer Patients Treated Definitively by IMRT with Concurrent Chemotherapy.
Radiat. Oncol. 2009, 4, 52.

[42] Basu, T.; Bhaskar, N.
Overview of Important “Organs at Risk” (OAR) in Modern Radiotherapy for Head and Neck Cancer (HNC). In Cancer Survivorship; IntechOpen: London, UK, 2019.

[43] Lambrecht, M.; Eekers, D.B.P.; Alapetite, C.; Burnet, N.G.; Calugaru, V.; Coremans, I.E.M.; Fossati, P.; Høyer, M.; Langendijk, J.A.; Romero, A.M.; et al.
Radiation Dose Constraints for Organs at Risk in Neuro‑Oncology; the European Particle Therapy Network Consensus.
Radiother. Oncol. 2018, 128, 26–36.

[44] Gondi, V.; Hermann, B.P.; Mehta, M.P.; Tomé, W.A.
Hippocampal Dosimetry Predicts Neurocognitive Function Impairment after Fractionated Stereotactic Radiotherapy for Benign or Low‑Grade Adult Brain Tumors.
Int. J. Radiat. Oncol. Biol. Phys. 2013, 85, 348–354.

[45] Brown, P.D.; Gondi, V.; Pugh, S.; Tomé, W.A.; Wefel, J.S.; Armstrong, T.S.; Bovi, J.A.; Robinson, C.; Konski, A.; Khuntia, D.; et al.
Hippocampal Avoidance during Whole‑Brain Radiotherapy plus Memantine for Patients with Brain Metastases: Phase III Trial NRG Oncology CC001.
J. Clin. Oncol. 2020, 38, 1019–1029.

[46] Pinkham, M.B.; Bertrand, K.C.; Olson, S.; Zarate, D.; Oram, J.; Pullar, A.; Foote, M.C.
Hippocampal‑Sparing Radiotherapy: The New Standard of Care for WHO Grade II and III Gliomas?
J. Clin. Neurosci. 2014, 21, 86–90.

[47] Goodman, K.A.; Regine, W.F.; Dawson, L.A.; Ben‑Josef, E.; Haustermans, K.; Bosch, W.R.; Turian, J.; Abrams, R.A.
RTOG Consensus Panel Guidelines for CTV Delineation in Postoperative Treatment of Pancreatic Head Cancer.
Int. J. Radiat. Oncol. Biol. Phys. 2012, 83, 901–908.

[48] Yeoh, E.; Botten, R.; Di Matteo, A.; Tippett, M.; Hutton, J.; Fraser, R.; Dinning, P.G.; Wattchow, D.
Pudendal Nerve Injury Impairs Anorectal Function and Quality of Life ≥2 Years after 3D‑CRT for Prostate Cancer.
Acta Oncol. 2018, 57, 456–464.

[49] Kovtun, K.A.; Yeo, W.P.; Phillips, C.H.; Viswanathan, A.; Baldini, E.H.
Ovary‑Sparing Radiation Planning Techniques for Soft Tissue Sarcoma of the Buttock and Thigh.
Sarcoma 2017, 2017, 2796925.

[50] Vyfhuis, M.A.L.; Fellows, Z.; McGovern, N.; Zhu, M.; Mohindra, P.; Wong, J.; Nichols, E.M.
Preserving Endocrine Function in Premenopausal Women Undergoing Whole‑Pelvis Radiation for Cervical Cancer.
Int. J. Part. Ther. 2019, 6, 10–17.

[51] Du, Z.; Qu, H.
Relationship between Ovarian Function and Ovarian Limited Dose in Radiotherapy Post‑Ovarian Transposition in Young Cervical Cancer Patients.
Cancer Med. 2017, 6, 508–515.

[52] Polanowski, P.; Wydmański, J.; Tukiendorf, A.; Składowski, K.
Analysis of Absorbed Dose by Pancreas during Gastric Cancer Radiotherapy.
Radiother. Oncol. 2020, 151, 20–23.

[53] Gemici, C.; Yaprak, G.; Ozdemir, S.; Baysal, T.; Seseogullari, O.O.; Ozyurt, H.
Volumetric Decrease of Pancreas after Abdominal Irradiation: Time to Consider Pancreas as an OAR.
Radiat. Oncol. 2018, 13, 238.

[54] Palmisciano, P.; Ogasawara, C.; Ogasawara, M.; Ferini, G.; Mazzei, M.M.; Marletta, D.; Rifatto, C.; Risoleti, E.V.I.; et al.
Stereotactic Body Radiotherapy in Non‑Operable Lung Cancer Patients.
Clin. Transl. Oncol. 2016, 18, 1158–1159.

[55] Uehara, T.; Monzen, H.; Tamura, M.; Inada, M.; Otsuka, M.; Doi, H.; Matsumoto, K.; Nishimura, Y.
Feasibility of VMAT with Halcyon™ Linac for Total Body Irradiation.
Radiat. Oncol. 2021, 16, 236.

[56] De Felice, F.; Marchetti, C.; Marampon, F.; Cascialli, G.; Muzii, L.; Tombolini, V.
Radiation Effects on Male Fertility.
Andrology 2019, 7, 2–7.

[57] Hoskin, P.J.; Colombo, A.; Henry, A.; Niehoff, P.; Paulsen Hellebust, T.; Siebert, F.A.; Kovacs, G.
GEC/ESTRO Recommendations on HDR Afterloading Brachytherapy for Localised Prostate Cancer: Update.
Radiother. Oncol. 2013, 107, 325–332.

[58] Henry, A.; Pieters, B.R.; Siebert, F.A.; Hoskin, P.
GEC‑ESTRO ACROP Prostate Brachytherapy Guidelines.
Radiother. Oncol. 2022, 167, 244–251.

[59] Susan, S.G.
Anatomy: The Anatomical Basis of Clinical Practice, 2nd ed.; Elsevier: Amsterdam, The Netherlands, 2020.

[60] Feng, M.; Moran, J.M.; Koelling, T.; Chughtai, A.; Chan, J.L.; Freedman, L.; Hayman, J.A.; Jagsi, R.; Jolly, S.; Larouere, J.; et al.
Development and Validation of a Heart Atlas to Study Cardiac Exposure to Radiation Following Breast‑Cancer RT.
Int. J. Radiat. Oncol. Biol. Phys. 2011, 79, 10–18.

[61] Duane, F.; Aznar, M.C.; Bartlett, F.; Cutter, D.J.; Darby, S.C.; Jagsi, R.; Lorenzen, E.L.; McArdle, O.; McGale, P.; Myerson, S.; et al.
A Cardiac Contouring Atlas for Radiotherapy.
Radiother. Oncol. 2017, 122, 416–422.
